ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.

85,013 comparisons

Most participants first33,758 with no events in either group come last961 to 980 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Newer DA-BLS Training Program vs Current BLS Training Program: deaths from any cause1,401 of 1,486

8,090 of 8,641

0.7 points

-0.7 to 1.9

10,127NCT02142387

Effects of a New Dispatcher-Assisted Basic Life Support Training Program

Districts Which Implement Newer DA-BLS Training Program vs Districts Which Keep Traditional BLS Training Program: Number of Participants With Good Neurological Recovery42 of 1,486

316 of 8,641

-0.8 points

-1.7 to 0.2

10,127NCT02142387

Effects of a New Dispatcher-Assisted Basic Life Support Training Program

Newer DA-BLS Training Program vs Current BLS Training Program: serious adverse events1,401 of 1,486

8,090 of 8,641

0.7 points

-0.7 to 1.9

10,127NCT02142387

Effects of a New Dispatcher-Assisted Basic Life Support Training Program

Copayment Intervention Arm vs Usual Care Arm: deaths from any cause16 of 6,135

8 of 3,967

0.1 points

-0.2 to 0.2

10,102NCT02406677

Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study

Tranexamic Acid vs Placebo: Number of Participants With Postpartum Infectious Complications162 of 5,080

125 of 5,009

0.7 points

0.0 to 1.3

10,089NCT03364491

Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean

Xylitol vs Control: deaths from any cause0 of 4,549

2 of 5,520

-0.0 points

-0.1 to 0.1

10,069NCT02333227

Saving Lives at Birth: Primary Prevention of Periodontal Disease in Relation to Preterm Birth in Malawi

Xylitol vs Control: serious adverse events0 of 4,549

2 of 5,520

-0.0 points

-0.1 to 0.1

10,069NCT02333227

Saving Lives at Birth: Primary Prevention of Periodontal Disease in Relation to Preterm Birth in Malawi

Tranexamic Acid vs Placebo: Number of Participants With Seizure Activity That Was Not Seen Prior to Study Enrollment2 of 5,069

0 of 4,996

0.0 points

-0.0 to 0.1

10,065NCT03364491

Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean

Tranexamic Acid vs Placebo: Number of Participants With a Thromboembolic Event (Venous or Arterial), Ischemic Stroke, or Myocardial Infarction12 of 5,069

13 of 4,996

-0.0 points

-0.2 to 0.2

10,065NCT03364491

Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean

Tranexamic Acid vs Placebo: Number of Mothers Who Died or Had Thromboembolic Events (Venous or Arterial), Ischemic Stroke, Myocardial Infarction, New-onset Seizure Activity, or Were Admitted to the Intensive Care Unit for More Than 24 Hours35 of 5,069

32 of 4,996

0.0 points

-0.3 to 0.4

10,065NCT03364491

Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean

Functional Diagnostic Tests vs Anatomic Diagnostic Test: serious adverse events161 of 5,007

168 of 4,996

-0.1 points

-0.9 to 0.6

10,003NCT01174550

PROspective Multicenter Imaging Study for Evaluation of Chest Pain

Primary Vaccination Group vs Booster Vaccination Group: serious adverse events204 of 6,851

59 of 3,149

1.1 points

0.4 to 1.7

10,000NCT01981967

Post-licensure Safety Study of IMOJEV® in Thailand

Brief Clinician Education vs Clinical Decision Support Nudges and Brief Clinician Education: PSA Screening in Older Men1,675 of 5,169

1,373 of 4,811

3.9 points

2.1 to 5.7

9,980NCT04289753

Behavioral Economics Applications to Geriatrics Leveraging EHRs R33 Trial

Vitamins vs Placebo: Pregnancy Associated Hypertension1,457 of 4,993

1,322 of 4,976

2.6 points

0.9 to 4.4

9,969NCT00135707

Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)

Vitamins vs Placebo: Severe or Mild Pregnancy-associated Hypertension With a Fetus That Was Small for Gestational Age (Below the 3rd Percentile) Adjusted for Sex and Race or Ethnic Group60 of 4,993

46 of 4,976

0.3 points

-0.1 to 0.7

9,969NCT00135707

Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)

Vitamins vs Placebo: Severe or Mild Pregnancy-associated Hypertension With an Indicated Preterm Birth Before 32 Weeks of Gestation Owing to Hypertension-related Disorders13 of 4,993

16 of 4,976

-0.1 points

-0.3 to 0.2

9,969NCT00135707

Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)

Vitamins vs Placebo: Severe or Mild Pregnancy-associated Hypertension With Elevated Liver Enzyme Levels26 of 4,993

33 of 4,976

-0.1 points

-0.5 to 0.2

9,969NCT00135707

Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)

Vitamins vs Placebo: Severe or Mild Pregnancy-associated Hypertension With Thrombocytopenia21 of 4,993

31 of 4,976

-0.2 points

-0.5 to 0.1

9,969NCT00135707

Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)

Vitamins vs Placebo: Creatinine ≥1.5 mg/dl (133 μmol/Liter)9 of 4,993

12 of 4,976

-0.1 points

-0.3 to 0.1

9,969NCT00135707

Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)

Vitamins vs Placebo: Severe Hypertension210 of 4,993

204 of 4,976

0.1 points

-0.7 to 0.9

9,969NCT00135707

Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=49

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT02142387-deaths",
        "title": "Newer DA-BLS Training Program vs Current BLS Training Program: deaths from any cause",
        "summary": "1401 of 1486 against 8090 of 8641; risk difference 0.7 points, 95% interval -0.7 to 1.9; NCT02142387, Effects of a New Dispatcher-Assisted Basic Life Support Training Program",
        "record": "/library/comparisons/NCT02142387-deaths",
        "nct_id": "NCT02142387",
        "kind": "deaths",
        "participants": 10127,
        "risk_difference": {
          "value": 0.006565229492935032,
          "lower": -0.007338595470668225,
          "upper": 0.018532179697545677
        },
        "group_1": "1,401 of 1,486",
        "group_2": "8,090 of 8,641",
        "difference": "0.7 points",
        "interval": "-0.7 to 1.9",
        "trial_title": "Effects of a New Dispatcher-Assisted Basic Life Support Training Program"
      },
      {
        "id": "NCT02142387-fd98bd15",
        "title": "Districts Which Implement Newer DA-BLS Training Program vs Districts Which Keep Traditional BLS Training Program: Number of Participants With Good Neurological Recovery",
        "summary": "42 of 1486 against 316 of 8641; risk difference -0.8 points, 95% interval -1.7 to 0.2; NCT02142387, Effects of a New Dispatcher-Assisted Basic Life Support Training Program",
        "record": "/library/comparisons/NCT02142387-fd98bd15",
        "nct_id": "NCT02142387",
        "kind": "outcome",
        "participants": 10127,
        "risk_difference": {
          "value": -0.008306046029578542,
          "lower": -0.016700323930222104,
          "upper": 0.002113597167166449
        },
        "group_1": "42 of 1,486",
        "group_2": "316 of 8,641",
        "difference": "-0.8 points",
        "interval": "-1.7 to 0.2",
        "trial_title": "Effects of a New Dispatcher-Assisted Basic Life Support Training Program"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "None stated"
    }
  ],
  "next": "/api/comparisons/v1?page=50",
  "request_id": "O_kbJuoAxN7IvlG8"
}
trial-comparisons-2026-03-23-0.1.0Next page

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Open193,990 genes2026-11-11

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Open611,552 trials2026-11-12

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

For invited accounts.

Opens sequences.conductscience.org

By invitation39,249,078 sequences2026-11-05

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?